The fact that we are not seeing any insider buying (and all we do see is prescheduled Brent Larson selling) tells me many things:
1) Manocept is complete nonsense. When Navidea tries to list the MT subsidiary on the TASE, I bet it goes down daily. The way NAVB has performed since being on the TASE certainly has not impressed Israeli investors.
2) 4694 will be thrown away for next to nothing.
3) Navidea is not worth buying out - if they were, it would have happened long ago at this sub $2 share price.
4) The 12 member sales team is just another expense that the company can't really afford. And very sadly, the sales teams "best" effort only added $1 million in revenue for Navidea. Their 12 salaries are likely much more than $1 million. Even when the company APPEARS to be acting wise, they're really just wasting more money. Lovely!
5) The NAVB shareholder will be treated very poorly if and when a real MT spinoff is ever announced. The number of shares in MT that will be awarded to NAVB shareholders will be minimal. Perhaps 20% of the initial MT float will be distributed AND AS RESTRICTED STOCK (and then only sellable in 3 years).
If all of my points are wrong, then Gonzalez himself would be buying NAVB shares, especially at 1.84, instead of buying more black beans and tacos. Too many investors have already bought into his nonsense thus far and are now very unhappy. Those of us that have been here for more than a year or two are just accustomed to Navidea fraud and mismanagement. It took 15 million TASE shares to move NAVB to 2.40 for a day. It will take hundreds of millions of shares to ever get it back there. Navidea executives seem to enjoy laughing at and mocking their own shareholders daily. May their party end soon!
